Pharmaxis has one product available in market, a bronchial provocation test called Aridol or Osmohale. It is approved throughout the world for identifying airway hyperresponsiveness, a key clinical feature of asthma.
For information regarding the availability of Aridol please refer to our Distributors.
For reporting of any Adverse Events please email adverse.events@pharmaxis.com.com.au or fax +61 2 9454 7255
For information related to our products, clinical trials or medical research, contact:
Phone: +61 2 9454 7264
Email Address
med.info@pharmaxis.com.au
